SCHEMBL4313353

SCHEMBL4313353

O=C1CNC(=O)N1c1ccccc1C=Cc1n[nH]c2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 10/20 0.43
▸ KDR P35968 5/20 0.43
▸ CDK4 P11802 4/20 0.43
▸ AURKA O14965 4/20 0.43
▸ AURKB Q96GD4 4/20 0.43
▸ RIPK1 Q13546 2/20 0.43
▸ BMPR1B O00238 1/20 0.43
▸ PLK4 O00444 1/20 0.43
▸ STK25 O00506 1/20 0.43
▸ CIT O14578 1/20 0.43
▸ RIOK3 O14730 1/20 0.43
▸ IKBKB O14920 1/20 0.43
▸ GAK O14976 1/20 0.43
▸ DCLK1 O15075 1/20 0.43
▸ CHUK O15111 1/20 0.43
▸ MUSK O15146 1/20 0.43
▸ EPHB6 O15197 1/20 0.43
▸ PDPK1 O15530 1/20 0.43
▸ MAP3K13 O43283 1/20 0.43
▸ DAPK3 O43293 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313347 1.00 CHEK1 (0.43) CHEK1KDRCDK4AURKAAURKB
SCHEMBL4317807 0.86 CHEK1 (0.43) CHEK1KDRCDK4AURKAAURKB
SCHEMBL4317798 0.86 CHEK1 (0.43) CHEK1KDRCDK4AURKAAURKB
SCHEMBL4327512 0.81 NR1H3 (0.53) CHEK1KDRCDK4AURKAAURKB
SCHEMBL4327508 0.81 NR1H3 (0.53) CHEK1KDRCDK4AURKAAURKB
SCHEMBL4321117 0.81 NR1H3 (0.46) CHEK1KDRCDK4AURKAAURKB
SCHEMBL4327084 0.81 NR1H2 (0.43) CHEK1KDRCDK4AURKAAURKB
SCHEMBL4327077 0.81 NR1H2 (0.43) CHEK1KDRCDK4AURKAAURKB
SCHEMBL4321110 0.81 NR1H3 (0.46) CHEK1KDRCDK4AURKAAURKB
SCHEMBL4310164 0.80 AURKA (0.40) CHEK1KDRCDK4AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 CHEK1 3274/4885KDR 75/4885CDK4 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback